When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer

Vitiello, Pietro Paolo; BARDELLI, Alberto; Saoudi Gonzalez, Nadia

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Vitiello, Pietro Paolo
dc.contributor.author	BARDELLI, Alberto
dc.contributor.author	Saoudi Gonzalez, Nadia
dc.date.accessioned	2025-03-06T13:44:57Z
dc.date.available	2025-03-06T13:44:57Z
dc.date.copyright	2024
dc.date.issued	2025-02
dc.identifier.citation	Vitiello PP, Saoudi González N, Bardelli A. When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer. Mol Oncol. 2025 Feb;19(2):267–70.
dc.identifier.issn	1878-0261
dc.identifier.uri	http://hdl.handle.net/11351/12702
dc.description	Càncer colorectal; Resistència a medicaments; Medicina de precisió
dc.description.sponsorship	AB is supported by: FONDAZIONE AIRC under 5 per Mille 2018 – ID. 21091 program – P.I. Alberto Bardelli; AIRC under IG 2023 – ID. 28922 project – P.I. Alberto Bardelli; International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB) and AIRC (22795); IMI contract no. 101007937 PERSIST-SEQ; European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (TARGET, grant agreement no. 101020342) – P.I. Alberto Bardelli; PRIN (Progetti di Rilevante Interesse Nazionale) no. 2022CHB9BA – P.I. Alberto Bardelli. NSG is supported by a European Society for Medical Oncology (ESMO) Translational Research Fellowship. Any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO. Images were generated with biorender.com.
dc.language.iso	eng
dc.publisher	Wiley
dc.relation.ispartofseries	Molecular Oncology;19(2)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Medicaments antineoplàstics - Ús terapèutic
dc.subject	Recte - Càncer - Tractament
dc.subject	Còlon - Càncer - Tractament
dc.subject	Resistència als medicaments
dc.subject	Biologia molecular
dc.subject	Farmacologia molecular
dc.subject	Factor de creixement epidèrmic - Receptors
dc.subject.mesh	ErbB Receptors
dc.subject.mesh	Colorectal Neoplasms
dc.subject.mesh	Drug Resistance, Neoplasm
dc.subject.mesh	Antineoplastic Agents
dc.subject.mesh	/therapeutic use
dc.subject.mesh	Molecular Biology
dc.title	When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1002/1878-0261.13754
dc.subject.decs	receptores ErbB
dc.subject.decs	neoplasias colorrectales
dc.subject.decs	resistencia a los antineoplásicos
dc.subject.decs	biología molecular
dc.subject.decs	antineoplásicos
dc.subject.decs	/uso terapéutico
dc.relation.publishversion	https://doi.org/10.1002/1878-0261.13754
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Vitiello PP, Bardelli A] Department of Oncology, University of Torino, Italy. IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy. [Saoudi González N] IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	39470386
dc.identifier.wos	001344720400001
dc.rights.accessrights	info:eu-repo/semantics/openAccess